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Abstract
Strategies to combine aspirated marrow cells with scaffolds to treat connective tissue defects are
gaining increasing clinical attention and use. In situations such as large defects where initial
survival and proliferation of transplanted connective tissue progenitors (CTPs) is limiting,
therapeutic outcomes might be improved by using the scaffold to deliver growth factors that
promote the early stages of cell function in the graft. Signaling by the epidermal growth factor
receptor (EGFR) plays a role in cell survival and has been implicated in bone development and
homeostasis. Providing epidermal growth factor (EGF) in a scaffold-tethered format may sustain
local delivery and shift EGFR signaling to pro-survival modes compared to soluble ligand. We
therefore examined the effect of tethered EGF on osteogenic colony formation from human bone
marrow aspirates in the context of three different adhesion environments using a total of 39
donors. We found that tethered EGF, but not soluble EGF, increased the numbers of colonies
formed regardless of adhesion background, and that tethered EGF did not impair early stages of
osteogenic differentiation.
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Introduction
Bone marrow contains a diverse population of connective tissue stem and progenitor cells
that contribute to the formation of new tissues after injury. When marrow aspirate is plated
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in culture, these cells adhere, exhibit fibroblastic morphology, and proliferate to form
colonies with multilineage differentiation potential [1]. Such colony-forming cells -- about
one out of 20,000 nucleated marrow aspirate cells [2, 3] -- can form bone, cartilage and fat
when transplanted in vivo [4]. Colonies formed from marrow aspirates are heterogeneous in
size and appearance. This may reflect a spectrum of stem-to-early progenitor properties in
the population giving rise to colonies or the presence of progenitor populations from
multiple niches in native tissue. Various terminologies have been employed to describe the
culture-expanded and selected progeny of tissue derived progenitors from various sources,
including mesenchymal stem cells (MSCs) [5], skeletal stem cells [6], multipotential adult
progenitor cells [7, 8], and multipotent mesenchymal stromal cells [9]. The present work
characterizes properties of the mixed population of connective tissue progenitors (CTPs)
extracted from native bone marrow whose progeny can differentiate into one or more
connective tissues [10, 11]. Addition of autologous bone marrow aspirate containing CTPs
to bone grafts (including ceramics and demineralized bone matrix) is already clinically
practiced [12-14]. Recently, it has been shown in canine models of spinal fusion and
segmental defect repair that the success of bone grafts can be enhanced using selective
retention of CTPs over other nucleated cells based on the preferential adhesion of CTPs over
other non-CTP populations [15-17]. These results motivate additional studies aimed at
understanding and manipulating the CTP population in marrow-supplemented grafts to
improve healing.
Survival and function of CTPs following implantation are influenced by local environmental
cues. The scaffold or matrix used in the graft provides mechanical support and is a source of
adhesive molecules and soluble factors that regulate CTP behavior. While natural scaffolds
such as demineralized bone provide such cues, such scaffolds also have inherent limitations
in size, structure, mechanical properties, biological activity and other features from lot-to-
lot, thus motivating design of synthetic scaffolds with precise properties for particular
indications.
Providing signals that act on transplanted CTPs to enhance survival and proliferation,
upstream of differentiation programs, may enhance overall healing by increasing the number
of cells that are capable of forming bone. Ligands for the epidermal growth factor receptor
(EGFR) are candidates for such cues, as the EGFR plays important roles in bone
development and homeostasis [18-21], and is an important regulator of CTP behavior
[22-27]. Most importantly, EGFR signaling can expand a CTP pool without either
committing it to differentiation or interfering with subsequent differentiation cues [28].
Although in vitro studies typically employ soluble EGF, there are several potential
advantages in presenting EGF as a matrix-tethered molecule for applications in tissue
engineering [29] so that it is competent to bind and activate the EGFR, but not be
internalized and degraded. This mode mimics features of the physiological presentation of
EGFR ligands that act in juxtacrine fashion or are matrix-bound. The potential advantages
include a better control of local EGF concentration, reduction in receptor downregulation,
and prolonging overall signaling [29]. Tethered EGF (tEGF) may also alter the balance of
downstream signaling pathways activated by the EGFR compared to activation by soluble
EGF. tEGF, but not soluble EGF, enhances cell spreading and protects culture-expanded
human CTPs from pro-death inflammatory cues [30].
We therefore hypothesized that tEGF might also act beneficially on CTPs in fresh human
bone marrow aspirates. We tested the ability of tEGF to increase the number of osteogenic
CTP colonies generated from freshly aspirated human bone marrow plated in serum-
containing medium, and whether the effects of tEGF were influenced by variation of the
adhesive properties of the substrate.
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Materials and Methods
Ligand-Modified Culture Substrates
Substrates were prepared to present tEGF against an adhesion background of pre-adsorbed
fibronectin (FN), adsorbed serum proteins, or a branched minimal FN-derived adhesion
peptide designed to mimic the adhesion sites in the 9th-10th domains of FN. This peptide,
which we designate “PHSRN-(K)-RGD” contains two lysine-linked branches, one
containing a RGD-adhesion domain and the other a PHSRN-synergy sequence, and a GGC
stem attached to the lysine side chain for covalent linkage to the polymer [31]. Polymer-
coated glass slides modified with ligands of interest were prepared as described earlier [30]
with minor modifications to expand the range of adhesive ligands presented with tEGF. All
substrates were prepared from blends of two different poly(methyl methacrylate)-graft-
poly(ethylene oxide) (PMMA-g-PEO) amphiphilic comb copolymers [32]: (i) CC1 (32 wt%
PEO) resists cell adhesion unless modified with adhesion peptides and fosters high-density
ligand clustering [31-33]; and (ii) CC2 (20 wt% PEO) allows cell attachment mediated by
serum protein adsorption [30]. CC1 was activated with 4-nitrophenyl chloroformate (NPC)
(Alpha Aesar, Ward Hill, MA) [30, 33] to target the N-terminal amine of murine EGF, and
with N-[p-Maleimidophenyl]isocyanate (PMPI) (Pierce Biochemical, Rockford, IL) to target
thiol-terminated adhesion peptides, as described previously [31, 34]. Unmodified CC1,
unmodified CC2, PMPI-activated CC1, and NPC-activated CC1 were blended in specific
proportions to give a 20 mg/mL solution in toluene, spin-coated onto 18 mm square glass
coverslips pre-treated with Siliclad (Gelest Inc., Morrisville, PA) to a thickness of ~75 nm,
vacuum-dried, then modified by adhesion ligands and/or EGF (see below) to create 4 unique
polymer surfaces (Table 1), some of which were further treated by adsorption of FN or
serum.
Covalent linkage of the PHSRN-(K)-RGD peptide was accomplished by reacting substrates
with a 25 μM solution of the peptide in phosphate buffered saline (PBS) containing 10 mM
Tris(2-Carboxyethyl) phosphine hydrochloride (TCEP; Sigma, St. Louis, MO) at pH 7.5 for
2 hr at room temperature [31]. The peptide density was about 20,000 RGD/μm2 based on
previous measurements [31]. Covalent linkage of murine EGF (PeproTech, Rocky Hill, NJ)
to substrates, through the N-terminal amine of the EGF, was accomplished by incubating
substrates for 20-24 hr with a 25 μg/mL solution of EGF in 100 mM phosphate buffer (pH
8.5-8.7) at room temperature, followed by rinsing 3X and blocking unreacted sites with 100
mM Tris buffer (pH 9.0), to achieve a surface density of approximately 5000-7000 tethered
EGF/μμm2 [30]. Substrates presenting tEGF against the PHSRN-(K)-RGD adhesion
background were produced by sequential reaction of each ligand, because the PMPI reaction
with thiols and the NPC reaction with amines proceed at different values of pH [30, 31].
Where indicated, FN (Sigma, St. Louis, MO) was adsorbed to substrates 1 and 2 (Table 1)
by incubating substrates with a 10 μg/mL solution in PBS for 2 hr at room temperature,
rinsing 3X with PBS, then blocking for 1 hour at room temperature with 1% bovine serum
albumin (Sigma, St. Louis, MO), and rinsing 3X. FN coating was performed within a day of
use.
Bone Marrow Aspiration
Human bone marrow was obtained from 39 normal donors and patients presenting to Dr.
G.F. Muschler prior to an elective orthopedic procedure. All subjects were enrolled with full
informed consent under a protocol approved by the Institutional Review Board of the
Cleveland Clinic. 2 mL of bone marrow was isolated from the iliac crest of volunteers as
described previously [3, 33]. Briefly, bone marrow was aspirated into a 10-ml plastic
syringe containing 1 ml of saline containing 1000 units of heparin. Subsequent aspirates
were taken using identical technique through separate cortical perforations separated by at
Marcantonio et al. Page 3
Biomaterials. Author manuscript; available in PMC 2011 June 21.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
least 1 cm, moving posteriorly along the iliac crest. Four aspirates were harvested from each
side. The heparinized marrow sample from each site was suspended into 20 ml of MEM-α
containing 2 unit/ml Na-heparin and sealed in a 50-ml test tube for transportation to the cell
culture laboratory. All samples were harvested by Dr. G.F. Muschler.
The aspirated bone marrow was centrifuged for 10 minutes at 1500 RPM. The buffy coat
was isolated and re-suspended in complete medium, MEM-α (Invitrogen, Chicago, IL)
containing, 50 mg/ml sodium ascorbate (Sigma, St. Louis, MO), antibiotic-antimycotic
(Invitrogen, Chicago, IL), and 10% fetal bovine serum (BioWhittaker, Walkersville, MD,
USA), using a lot that was selected on the basis of enhancing osteogenic differentiation.
CTP/CFU Assay
Treated coverslips were placed in the wells of 2-chamber Lab-Tek culture slides (Nunc,
Rochester, NY), with one coverslip covering the bottom of each chamber on the slide,
sterilized under UV for 30 min, and seeded with 0.5 million cells (approximately 1.5 × 105
nucleated cells/cm2) in complete medium.
For each donor, 4 coverslips for each surface condition being examined were seeded with
bone marrow cells. In addition to comb copolymer surfaces, untreated glass surfaces were
also seeded, and served as the positive control for each donor.
Cultures were maintained at 37°C in a humidified atmosphere of 5% CO2 in air. The culture
medium was changed 48 h after plating and the non-adherent cells from each chamber were
replated on Lab-Tek slide surfaces. Where indicated, soluble EGF was added at 10 ng/mL at
plating and with each subsequent medium change.
The initial and replated cultures were maintained for 4 and 6 additional days, respectively.
Cultures were then washed twice with PBS, fixed, and stained with DAPI and for alkaline
phosphatase (AP) with VectorRed (Vector Labs, Burlingame, CA). Clusters of 8 or more
cells staining positive for AP were scored as an osteogenic colony. Colonies on original
substrates were defined as “early adherent colonies,” as they originated from cells that
adhered to the test surfaces within 48 h of plating. Colonies formed on Lab-Tek slides from
the replating of cells that were non-adherent at 48 h were defined as “late adherent
colonies.” Fig. 1A shows the schematic of the colony-forming unit (CFU) assay for CTP
colony formation.
Nine different combinations of adhesion and growth factor environments were studied (Fig.
1B), in 3 different subsets of combinations so that multiple conditions could be compared
using marrow from the same donor to account for patient-to-patient variability in CTP
prevalence. For each experimental condition, we measured the prevalence of osteogenic
colonies that formed per 1 million seeded cells and calculated relative colony forming
efficiency (CFE) on each surface by normalizing to the prevalence on the glass control
surfaces for that donor. The same procedure was applied with the late adherent colonies to
determine the normalized number of late adherent colonies that formed on glass after being
removed from a given experimental surface.
Image Analysis
Quantitative image analysis was performed on data from 8 donors where indicated, using a
procedure described previously [35]. Briefly, experimental and glass surfaces of fixed and
stained cells were imaged at 10X. 100 individual images were combined into a single image
such that colonies could be outlined and analyzed based on fluorescence, using software
developed by Powell et al. [35]. Following rendering of outlines by the software, images
were examined and colonies that were incorrectly outlined due to debris were adjusted
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manually by the reviewer. The following metrics were analyzed for each colony: the area of
the colony expressing AP above a threshold value (set by the reviewer) normalized to the
number of cells in the colony; the number of cells per colony; and the cell density per
colony. For each donor, the median value for each metric was assessed for all colonies and
normalized to the median value for colonies formed on glass controls.
Statistical Analysis
For each data set, every normalized data point was log base-2 transformed and an average
value for each experimental condition was calculated across all patients. 95% confidence
levels were calculated in log base-2 space. Three points for CFE had a measured value of 0,
and these values were converted to ½ the smallest non-zero CFE for the rest of the data set
for that condition, prior to the log transformation. Additionally, for two donors, the glass
control surfaces had 0 late adherent colonies, precluding normalization. These data were
therefore not included in the calculation of mean and confidence levels.
A Shapiro-Wilk test was used to assess the normality of each data set, and data sets were
assumed to be normal if p > 0.05. To test for statistical differences between surface
conditions, a two-way matched pairs t-test was performed in log base-2 space for each pair
of conditions. In the event that a data set for a surface condition was non-normally
distributed, a Wilcoxon signed-rank test was also used to test for significant differences
between surface conditions. Using p = 0.05 as the cutoff for significance, no differences in
statistical conclusions were observed for any statistical comparison with non-normally
distributed data sets using either the matched pair t-test or the Wilcoxon signed-rank test
with one exception described below. For all plots, the anti-log of all data, as well as the
mean and confidence intervals, are plotted on log base-2 axes. For plots containing data
from 12 donors or fewer, data points from a single donor are connected by a line.
Results
Colony Formation on Adhesion Peptides with tEGF
In the CFU assay, marrow aspirates are plated at a density of 1.5 × 105 nucleated cells/cm2,
non-adherent cells are removed after 48 hr, and after a total culture time of 6 days, the
number of colonies (8 or more cells in a cluster) is enumerated and the differentiation status
of each colony is analyzed. Differences in prevalence (i.e., number of colonies per 2 million
cells) may arise from differences in the number of CTPs present and adhering initially, entry
of CTPs into the cell cycle (activation), or differences in proliferation. These processes are
influenced by cues from the culture substrate and soluble medium components.
We first evaluated whether tEGF could enhance colony formation under conditions where
adhesion was expected to be the limiting process in colony formation, as tEGF has been
shown to enhance attachment and spreading of culture-expanded CTPs [30]. We therefore
used substrates that foster attachment through the minimal peptide adhesion moiety RGD
(using the PHSRN-(K)-RGD peptide) presented in a clustered format. While substrates
presenting minimal RGD peptides in such a clustered format support proliferation of
culture-expanded CTPs, the formation of colonies from human marrow aspirates on these
substrates is significantly diminished compared to control adhesion environments [33] even
though CTPs express integrins known to interact with RGD-containing matrix proteins [33,
36, 37].
We observed here an average CFE of 0.27 on PHSRN-(K)-RGD substrates, confirming that
colony formation on clustered RGD is significantly diminished compared to glass controls
(Fig. 2). tEGF increased colony formation on PHSRN-(K)-RGD almost 3-fold, resulting in
an average CFE of 0.73 (p < 0.00002). The minimal RGD adhesion sequence, even when
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presented in nanoclusters, is not sufficient to engender full adhesion and spreading by all
integrins that recognize the RGD sequence [38-41]. tEGF may be acting locally to enhance
actin polymerization and adhesion [42], allowing adhesion to an otherwise poorly adherent
substrate, or may be initiating inside-out activation of integrins [43] to enhance the fraction
of CTPs that adhere. We thus sought to determine whether tEGF would increase colony
formation on substrates expected to provide a greater level of intrinsic adhesion.
Colony Formation on Adsorbed Serum and FN
Osteogenic colony formation is typically assessed by plating cells onto glass or plastic
substrates in the presence of serum, so that adhesion is mediated by adsorbed serum
proteins. Plating marrow in serum on control comb co-polymer substrates that allow protein
adsorption (Blend 1 in Table 1; i.e, an “adsorbed serum” adhesion environment) we
observed a significant increase in colony formation (CFE = 0.41), compared to tethered
PHSRN-(K)-RGD peptide (0.27, p < 0.02) substrates alone (Fig. 2). Even on this more
favorable adhesion background, tEGF nearly doubled colony formation (CFE = 0.74, p <
0.00004). Because average CFE was < 1.0 (suggesting that CTP availability was not
depleted), we would expect the magnitude of the increase in colony formation to be similar
on adsorbed serum and PHSRN-(K)-RGD, if tEGF was increasing colony formation
primarily by stimulating proliferation post-adhesion and activation. However, in the
presence of tEGF, CFE was statistically similar on PHSRN-(K)-RGD and adsorbed serum (p
> 0.9).
Among the adhesion molecules in serum, FN has been shown to foster colony formation in
serum-free medium in a manner comparable to serum-supplemented medium. In addition to
the PHSRN and RGD sites in the 9th-10th domains, FN contains binding sites for integrin
α4β1, syndecans, and other receptors reported to be expressed by CTPs [36, 37, 44]. Hence,
FN may offer an adhesive environment more conducive to colony formation than the
minimal PHSRN-(K)-RGD sequence. Using a different cohort of donors than those studied
in Fig. 2, we found that colony formation on FN (CFE = 0.46) was statistically similar to
that for cells plated on adsorbed serum (CFE = 0.37, p > 0.09), and greater than on PHSRN-
(K)-RGD (CFE = 0.23, p < 0.004) (Fig. 3). Notably, tEGF increased colony formation for
cells on FN (CFE = 0.59, p < 0.005) (Fig. 3), behavior consistent with the effect of tEGF on
cells from this cohort plated on adsorbed serum or PHSRN-(K)-RGD (Fig. 3). Even though
CFE was much greater on FN than on RGD in the absence of tEGF, when EGF was tethered
to the substrate, CFE was similar on FN and on PHSRN-(K)-RGD, lending support to our
hypothesis that tEGF is increasing the adhesion, survival, and/or activation of CTPs, rather
than increasing proliferation.
Colony formation with soluble EGF
In culture-expanded human CTPs and in an immortalized human MSC cell line, soluble
EGF is far less effective than tEGF in promoting cell spreading and in protecting cells from
FasL-mediated cell death [33] and decreases colony formation from rabbit marrow cells
plated in the presence of serum [26]. In contrast, soluble EGF promotes colony formation
from human bone marrow cells on FN in serum-free medium to a degree comparable to
serum-supplemented medium [25]. When we add soluble EGF (10 ng/mL) to cells plated on
FN in serum-containing medium, colony formation is significantly decreased compared to
the control no EGF case (CFE = 0.32, p < 0.003) as shown in Fig. 3. Thus, soluble EGF
elicits a different response than tEGF, which significantly increased colony formation on FN
in serum-containing media (Fig. 3). Phenotypic differences between soluble EGF and tEGF
are also observed in the context of our two other adhesion environments, adsorbed serum
and PHSRN-(K)-RGD peptide (Fig. 4): tEGF increased colony formation on both substrates
(p < 0.04), whereas soluble EGF did not (p > 0.1).
Marcantonio et al. Page 6
Biomaterials. Author manuscript; available in PMC 2011 June 21.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Influence of Donor Population Characteristics
The prevalence and biological performance of CTPs from bone marrow is affected by age,
gender, and health of the donor [3], and it is possible that CTPs from different donor pools
may respond differently to extracellular cues such as tEGF. We therefore compared the
colony-forming responses of marrow aspirates from donors with a disease state,
osteoarthritis, to those of normal healthy donors. We found that tEGF significantly increased
CFE in both donor populations (Figs. 5A and 5B), on both PHSRN-(K)-RGD and adsorbed
serum (p < 0.006), demonstrating that the effects of tEGF are not limited to marrow from
healthy donors.
Indeed, the effects of tEGF were consistent across all 39 donors (Fig. 5C). Without tEGF,
colony formation was slightly increased on adsorbed serum (CFE = 0.33) compared to
PHSRN-(K)-RGD (CFE = 0.24, p < 0.006). However, with tEGF, CFE increased ~2.6X on
PHSRN-(K)-RGD (CFE = 0.62, p < 0.0001) and ~1.7X on serum (CFE = 0.57, p< 0.0001).
In the presence of tEGF, CFE was similar on serum and PHSRN-(K)-RGD (p > 0.2),
supporting our hypothesis that tEGF was enhancing the adhesion, survival, and/or activation
of CTPs.
Colony size on tEGF substrates
In diverse cell types, EGFR signaling influences downstream migration and proliferation
responses in addition to survival and adhesion. In the CFU assay employed here, where
colonies are examined visually following 6 days of culture, changes in cell proliferation and
migration rates would likely influence two measurable properties: the number of cells per
colony, and the density of cells in each colony (cells per unit area). We used a quantitative
image analysis algorithm (see Methods) to measure these properties for marrow-derived
CTPs plated on either PHSRN-(K)-RGD peptide or on adsorbed serum proteins, in the
presence and absence of tEGF, with the data normalized to those obtained on glass for each
donor. On the PHSRN-(K)-RGD peptide, the number of cells per colony (Fig. 6A) was
similar with or without tEGF (p > 0.7). However, on adsorbed serum, tEGF promoted an
increase in colony size (p < 0.002), suggestive of cell proliferation. Unlike changes in CFE,
increased cell proliferation with tEGF appears to be unique to serum-adsorbed surfaces,
suggesting that this effect is distinct from mechanisms underlying tEGF-enhanced CFE.
Cell density within the colonies also appeared to be differentially affected by the adhesive
substrate (Fig. 6B). Cell density was greater on PHSRN-(K)-RGD than on adsorbed serum
in the presence (p < 0.0008) or absence (p < 0.04) of tEGF, suggesting that the more diverse
components present in adsorbed serum elicited a greater cell migration response than the
simple PHSRN-(K)-RGD peptide. The adhesive environment was the dominant effect in
determining cell density, as for a particular adhesion environment, no significant differences
were observed in the presence of tEGF compared to its absence (Fig. 6B).
Osteogenic differentiation on tEGF substrates
Because EGFR-mediated signaling has been shown to influence the differentiation of culture
expanded CTPs [22, 28, 45], we assessed the relative values of AP expression by dividing
the area of a colony expressing AP above a threshold value by the number of cells within
that colony (see Methods for details of image analysis). Values for test substrates were
normalized to values for glass for the same donor. No significant differences were observed
in any of the test substrates compared to control class (p > 0.1 for all comparisons),
suggesting that tEGF neither enhances nor inhibits this early step along the osteogenesic
pathway. In 6 of 8 donors however, on PHSRN-(K)-RGD, the percent of AP positive cells
was decreased in the presence of tEGF, suggesting that the differentiation of CTPs derived
from some donors may be affected by tEGF under some adhesion conditions. More sensitive
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measures of osteogenic differentiation, including AP activity per cell and expression levels
of other osteogenic markers, may reveal functional differences between these conditions.
Discussion
Many envisioned applications of marrow-derived connective tissue stem and progenitor
cells in regenerative medicine require biomaterials that can direct the attachment, survival,
activation, proliferation, migration, and differentiation of these cells. To this end, we
investigated how an unconventional biophysical presentation of a ligand for EGFR
influences behavior of CTPs in fresh human bone marrow aspirates, with two major findings
of importance for CTP biology and use. First, we found that tethered tEGF, enhances colony
formation by primary CTPs independent of adhesion background (Figs. 2-5), and does so in
a way that does not appear to impair the early stages of osteogenic differentiation (Fig. 6C).
Second, we found that the effects of EGF on colony formation depend on its mode of
presentation. In contrast to tEGF, soluble EGF at the physiological concentration of 10 ng/
mL does not enhance colony formation, and slightly inhibits colony formation on FN (Figs.
3 and 4).
Although many facets of how culture-expanded human CTPs respond to EGFR ligands have
been described [22, 27, 28, 45], relatively little is known about how freshly-aspirated human
marrow-derived CTPs respond in this regard. In an elegant study, Gronthos and Simmons
showed that 90% of the colony-forming cells in fresh human marrow aspirates co-express
the EGFR and the marker Stro-1, and that when Stro-1 positive cells are plated on FN,
soluble EGF at concentrations as low as 1 ng/mL fosters colony formation to an equivalent
degree as plating in serum on plastic [25]. While we found soluble EGF to be slightly
inhibitory to colony formation on FN, these differences may be attributed to our mixed
population of cells and other complexities associated with adhesion and growth factor
signaling, as well as the inclusion of serum in our experimental protocol.
EGFR has several natural ligands and activates multiple divergent signaling pathways. The
duration and relative strengths of different signaling pathways activated by ligand-bound
EGFR are strongly influenced by receptor internalization and trafficking [46-48]. Ligands
that have low cell surface binding affinities or dissociate in the endosome, such as
transforming growth factor alpha and tenascin cytoactin-encoded EGF-like repeats,
preferentially signal through pathways localized at the cell surface, including PLCγ [49]. In
contrast, ligands that remain receptor-bound following internalization, such as EGF, drive
sustained signaling through Ras/ERK pathways during intracellular trafficking [47, 50, 51].
Pathways activated by the EGFR stimulate lamellipod extension, stabilization of focal
contacts, cell contraction, and multiple other events involved in adhesion and spreading
processes that are essential early events in colony formation. Under conditions where the
number or strength of adhesion receptor-extracellular matrix bonds is low -- e.g., where the
number of matrix adhesion sites is limiting, the adhesion ligand has low affinity for the
receptor, or the matrix proteins are only weakly adsorbed to the substrate -- stimulation by
EGF (or other growth factors) can cause cell rounding and detachment by creating an
unfavorable ratio of cell contractile force to adhesion force [52]. The polymer substrates we
used for analyzing colony formation in response to tethered and soluble EGF inhibit protein
binding either partially (adsorbed serum and FN conditions) or completely (RGD condition)
[33]. Although we have previously observed that several cell lines are highly adhesive on
similar RGD substrates [33, 53], we observed here that the number of colonies formed from
human marrow aspirates plated on the three test adhesion environments (RGD, FN,
adsorbed serum proteins) was reduced compared to glass for the control condition (no EGF),
suggesting these substrates are inherently less adhesive for CTPs than glass in the presence
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of serum. In this setting, soluble EGF may further impair colony formation on these
substrates by pushing cell contraction to overwhelm adhesion forces. However, because
tEGF preferentially stimulates pathways localized to the cell surface, including very rapid
local actin polymerization and lamellipod extrusion [42], the overall balance of signaling
pathways on tEGF may favor the adhesion, and thus survival and activation, of attached
cells, conditions permissive for proliferation and colony formation.
We have focused on the potential role of EGFR stimulation to affect events that occur in the
first few hours to days following transplantation of freshly-aspirated human CTPs, reasoning
that increasing attachment, survival, activation, and proliferation of CTPs at this stage may
facilitate more robust bone formation in large defects. Although our results suggest that
tEGF does not impair osteogenic differentiation at least at the early stage examined here
(Fig. 6C), it is difficult to predict how tEGF may influence downstream events in bone
wound healing in vivo due to the complexity of factors at play and the fact that its direct
effects would be limited to the scaffold surface. Studies in mice with genetically reduced
EGFR levels, and of osteoblastic cells stimulated with EGFR ligands in vitro, suggest that
activation of EGFR simulates proliferation of progenitor cells and inhibits osteoblastic
differentiation [20, 27, 53], while other studies support EGF promotion of proliferation in
vitro without inhibiting osteogenic differentiation [28, 45] or enhancement of differentiation
of culture-expanded CTPs [22, 54]. In addition to the context-dependent effects on
osteogenic cells expressing EGFR, EGFR signaling promotes angiogenesis [55] and
influences osteoclast activity [56]. Hence, in vivo studies are required to determine if the
integrated effects elicited by tEGF offer clinical advantages in tissue regeneration. Our
preliminary studies here and elsewhere [30] motivate such in vivo studies, in both 2D and
3D, as they demonstrate that tEGF exerts positive influences on CTP behaviors important in
the early post-transplant period.
Conclusion
In conclusion, this study has shown that tEGF enhances human CTP osteogenic colony
formation across multiple adhesion conditions via a mechanism most likely related to
improved survival and activation of CTPs as well as proliferation. The effects of tEGF stand
in contrast to those of soluble EGF. Hence, tEGF may be a useful molecular signal in
transplantation of human marrow-derived CTPs for regenerative medicine.
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Figure 1.
Experimental setup used to examine the effect of tethered epidermal growth factor (tEGF)
on osteogenic connective tissue progenitor (CTP) colony formation from freshly aspirated
bone marrow. (A) Protocol for bone marrow aspirate colony forming unit assay. Open
circles: non-adherent bone marrow cells. Closed circles: colonies of adherent cells derived
from adherent connective tissue progenitors. (B) Osteogenic CTP colony formation was
studied without epidermal growth factor, with tEGF, or with soluble epidermal growth
factor at 10 μg/mL on three adhesive conditions: adsorbed serum, pre-adsorbed fibronectin,
or tethered PHSRN-(K)-RGD peptide, as depicted schematically. Abbreviations: PEO,
poly(ethylene oxide); serum, adsorbed serum; FN, pre-adsorbed fibronectin; RGD, tethered
PHSRN-(K)-RGD peptide; tEGF, tethered epidermal growth factor; sEGF, soluble
epidermal growth factor.
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Figure 2.
Tethered epidermal growth factor (tEGF) enhances connective tissue progenitor (CTP)
adherent colony formation. The relative colony forming efficiency (CFE) of adherent CTPs
was measured for a total of 18 donors with an average age of 62. Each point represents data
from an individual donor on a given experimental surface condition. Error bars indicate
mean values and 95% confidence levels for each experimental condition. p-values are
calculated using a matched-pairs t-test (matched by donor) and are shown in the tables. The
osteogenic colony formation, indicated by CFE, of adherent CTPs from freshly aspirated
bone marrow on tethered PHSRN-(K)-RGD peptide and adsorbed serum is increased in the
presence of tEGF (p < 0.00004). Without tEGF, CFE is greater on adsorbed serum than on
PHSRN-(K)-RGD (p < 0.02), while with tEGF, CFE is similar on PHSRN-(K)-RGD and
adsorbed serum (p > 0.9). Abbreviations: RGD, tethered PHSRN-(K)-RGD peptide; tEGF,
tethered epidermal growth factor; serum, adsorbed serum.
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Figure 3.
Tethered epidermal growth factor (tEGF) enhances connective tissue progenitor (CTP)
colony formation on both minimally adhesive and highly adhesive substrates. The
osteogenic colony formation, indicated by relative colony forming efficiency (CFE), of
CTPs from freshly aspirated bone marrow was increased on tethered PHSRN-(K)-RGD
peptide, adsorbed serum and pre-adsorbed fibronectin in the presence of tEGF (p < 0.03).
CFE is decreased on fibronectin in the presence of soluble epidermal growth factor at 10 ng/
mL (p < 0.003). Each point represents CFE for an individual donor on a given experimental
surface condition for a total of 12 donors with an average age of 51. Lines connect data for a
specific donor. Error bars indicate mean CFE and 95% confidence levels for each
experimental condition. p-values are calculated using a matched-pairs t-test (matched by
donor) and are shown in the table. Abbreviations: RGD, tethered PHSRN-(K)-RGD peptide;
tEGF, tethered epidermal growth factor; serum, adsorbed serum; FN, pre-adsorbed
fibronectin; sEGF, soluble epidermal growth factor.
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Figure 4.
Tethered epidermal growth factor (tEGF), but not soluble epidermal growth factor, enhances
connective tissue progenitor (CTP) colony formation. The osteogenic colony formation,
indicated by relative colony forming efficiency (CFE), of CTPs from freshly aspirated bone
marrow was increased on tethered PHSRN-(K)-RGD peptide and adsorbed serum in the
presence of tEGF (p < 0.04). Soluble epidermal growth factor at 10 ng/mL does not
significantly affect CFE for either adhesive condition (p > 0.05). Each point represents CFE
for an individual donor on a given experimental surface condition for a total of 9 donors
with an average age of 58. Lines connect data for a specific donor. Error bars indicate mean
CFE and 95% confidence levels for each experimental condition. p-values are calculated
using a matched-pairs t-test (matched by donor) and are shown in the table. Abbreviations:
RGD, tethered PHSRN-(K)-RGD peptide; tEGF, tethered epidermal growth factor; serum,
adsorbed serum; sEGF, soluble epidermal growth factor.
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Figure 5.
Tethered epidermal growth factor (tEGF) enhances connective tissue progenitor (CTP)
colony formation in multiple donor populations. Colony forming efficiency (CFE) data was
pooled from all three donor cohorts to assess the effect of tEGF on osteogenic colony
formation in both healthy volunteers as well as donors with osteoarthritis. Each point
represents CFE for an individual donor on a given experimental surface condition. Error
bars indicate mean CFE and 95% confidence levels for each experimental condition. p-
values are calculated using a matched-pairs t-test (matched by donor). (A) CFE as measured
in 7 healthy donors with average age of 39, with lines connecting data for each specific
donor. tEGF enhances CFE on both tethered PHSRN-(K)-RGD peptide and adsorbed serum
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(p < 0.008). (B) CFE as measured in 24 donors with osteoarthritis with average age of 63.
As observed with healthy donors, tEGF enhances CFE on both tethered PHSRN-(K)-RGD
peptide and adsorbed serum (p < 0.00002). (C) Data pooled from all 39 donors, with
average age of 58 (8 donors presented with indications other than or in addition to
osteoarthritis). tEGF enhances CFE on both tethered PHSRN-(K)-RGD peptide and
adsorbed serum (p < 0.00001). In the absence of tEGF, CFE is enhanced on adsorbed serum
compared to tethered PHSRN-(K)-RGD peptide (p < 0.006). Abbreviations: RGD, tethered
PHSRN-(K)-RGD peptide; tEGF, tethered epidermal growth factor; serum, adsorbed serum.
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Figure 6.
Connective tissue progenitor colony size, cell density, and differentiation status as measured
with quantitative image analysis. Data was compiled from 8 donors with an average age of
65. Individual points represent median values for an experimental substrate normalized to
median values on control surfaces for each donor. Lines connect data points from a specific
donor and error bars indicate mean colony values and 95% confidence levels for each
experimental condition. p-values are calculated using a matched-pairs t-test (matched by
donor). (A) Tethered epidermal growth factor (tEGF) increases the number of cells per
colony on adsorbed serum (p < 0.002), but not on tethered PHSRN-(K)-RGD (p > 0.7). (B)
tEGF did not affect cell density on either tethered PHSRN-(K)-RGD peptide or adsorbed
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serum (p > 0.3). However, cell density was greater on tethered PHSRN-(K)-RGD peptide
compared to adsorbed serum, both with and without tEGF (p < 0.05). (C) To assess
differentiation, the area of a colony expressing alkaline-phosphatase (AP) above a given
threshold was normalized to the number of cells in the colony. Using this metric, tEGF was
not observed to promote a statistically significant increase in the number of cells within a
colony expressing AP (p > 0.1). However, on PHSRN-(K)-RGD, tEGF decreased the
number of cells expressing AP in 6 of 8 donors. Abbreviations: RGD, tethered PHSRN-(K)-
RGD peptide; tEGF, tethered epidermal growth factor; serum, adsorbed serum; AP, alkaline
phosphatase.
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